Aprea Therapeutics Inc Forecast, price target & analysts
Aprea Therapeutics Inc Target price 2025 - Analyst rating & recommendation
Aprea Therapeutics Inc Classifications & Recommendation:
Aprea Therapeutics Inc Price Target
| Target Price | $10.71 |
| Price | $1.74 |
| Potential |
515.52%
register free of charge
|
| Number of Estimates | 4 |
|
4 Analysts have issued a price target Aprea Therapeutics Inc 2026 .
The average Aprea Therapeutics Inc target price is $10.71.
This is
515.52%
register free of charge
$11.55
563.79%
register free of charge
$10.10
480.46%
register free of charge
|
|
| A rating was issued by 9 analysts: 8 Analysts recommend Aprea Therapeutics Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Aprea Therapeutics Inc stock has an average upside potential 2026 of
515.52%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 1.50 | 0.67 |
| 158.62% | 55.53% | |
| EBITDA Margin | -953.33% | -2,675.84% |
| 64.23% | 180.68% | |
| Net Margin | -864.00% | -1,317.12% |
| 64.93% | 52.44% |
5 Analysts have issued a sales forecast Aprea Therapeutics Inc 2025 . The average Aprea Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Aprea Therapeutics Inc EBITDA forecast 2025. The average Aprea Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
5 Aprea Therapeutics Inc Analysts have issued a net profit forecast 2025. The average Aprea Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.35 | -1.59 |
| 40.51% | 32.34% | |
| P/E | negative | |
| EV/Sales | negative |
5 Analysts have issued a Aprea Therapeutics Inc forecast for earnings per share. The average Aprea Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Aprea Therapeutics Inc...
Current Aprea Therapeutics Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 15 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Dec 17 2024 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 18 2024 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Oct 24 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 15 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Dec 17 2024 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 18 2024 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Oct 24 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
